ERBB2 and carcinosarcoma: For instance, the finding that the addition of trastuzumab to chemotherapy for high expressers of Her2/neu in endometrial serous carcinoma improved overall survival [11], has now been extended to other endometrial carcinomas, including carcinosarcomas.